Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Alterity Therapeutics (ATHE) Operating Expenses (2016 - 2025)

Alterity Therapeutics has reported Operating Expenses over the past 4 years, most recently at -$5.6 million for Q4 2018.

  • For Q4 2018, Operating Expenses fell 75.28% year-over-year to -$5.6 million; the TTM value through Jun 2019 reached -$8.8 million, down 801.76%, while the annual FY2025 figure was $12.9 million, 100.2% up from the prior year.
  • Operating Expenses for Q4 2018 was -$5.6 million at Alterity Therapeutics, down from -$3.2 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $4.5 million in Q4 2016 and troughed at -$5.6 million in Q4 2018.
  • A 4-year average of -$64874.3 and a median of $449313.0 in 2015 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: increased 8.79% in 2016 and later plummeted 171.82% in 2017.
  • Year by year, Operating Expenses stood at $4.1 million in 2015, then grew by 8.79% to $4.5 million in 2016, then plummeted by 171.82% to -$3.2 million in 2017, then crashed by 75.28% to -$5.6 million in 2018.
  • Business Quant data shows Operating Expenses for ATHE at -$5.6 million in Q4 2018, -$3.2 million in Q4 2017, and $4.5 million in Q4 2016.